As a healthcare provider, we prescribe only medicines that have been shown to be safe and effective through extensive clinical trials. Our clinicians will work with you to determine the most appropriate length of treatment based on your individual circumstances.
Clinical trials demonstrated the safety and effectiveness of GLP-1 medicines for diabetes before the MHRA approved semaglutide for the long-term treatment of obesity. The trials also showed a reduced risk of adverse cardiovascular events, including heart attack and stroke.
Liraglutide, another GLP-1 medicine, is also approved for treating obesity. Treatment has been shown to improve systolic blood pressure and waist circumference compared with placebo.
Tirzepatide, a dual GIP and GLP-1 receptor agonist, was more recently approved by the MHRA. Its initial trials demonstrated safety and effectiveness in diabetes before it was approved for weight management.
Tirzepatide has a similar side-effect profile to semaglutide, while trial data showed greater weight loss over a comparable period. Weight reduction was also accompanied by improvements in cardiovascular and metabolic risk factors, including blood pressure, waist circumference, and lipid levels.